Charles River Laboratories International, Inc. (CRL)
Healthcare · Medical - Diagnostics & Research · Data as of 2026-10-22
Bottom line
CRL is trading at a premium to its history, near its historical resistance zone, and recent volume shows no clear direction. Historically, this combination has called for extra caution. Past patterns are not a guarantee of future results.
Valuation — Expensive against its own asset value (Red)
CRL is losing money, so we lean on its balance sheet: price-to-book of 5.1× versus its own typical 3.5×. Day-to-day operations still generate cash (EV/EBITDA 78.4×), so the losses come from costs like interest and depreciation rather than the core business. Despite the accounting losses, it already generates positive free cash flow. Analysts currently expect it to turn profitable around 2026.
Price zones — Near its historical resistance zone (Red)
At $339.66, the stock is close to the upper end of its recent range. Over the past year CRL has traded between $146.20 and $351.21; its historical support zone sits near $292.66 and resistance near $351.21. It is above both its 50- and 200-day averages, which has historically signalled an uptrend.
52-week range $146.20–$351.21 · 50-day average $292.66 · 200-day average $217.46
Money flow — No clear direction (Yellow)
Buying and selling volume in CRL have been fairly balanced recently, with no strong accumulation or distribution pattern. Volume on up days has been about 1.0× volume on down days over the last 30 sessions.
Dividends & company facts
CRL doesn't pay a dividend, but it bought back $360 million of its shares in fiscal 2025, about 2.5% of its market value. Its share count fell 1.7% over the past year and 5.5% over five.
- Buybacks
- 2.49% (fiscal 2025)
- Shares, past year
- -1.7%
- Revenue, 12 months
- $4.0B
- Profit, 12 months
- $-238M
- Employees
- 19,000
- CEO
- Birgit Girshick
- Headquarters
- Wilmington, MA
- Listed since
- 2000 · NYSE
About the company
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region.
Related stocks
一句话结论
CRL 相对自身历史处于溢价水平，接近其历史阻力区，近期成交量没有明确方向。从历史来看，这样的组合需要格外谨慎。过去的形态并不能保证未来的结果。
估值 — 相对自身资产价值偏高
CRL 目前处于亏损，因此我们更多地看资产负债表：市净率为 5.1×，而它自身惯常的水平是 3.5×。日常经营仍在产生现金（EV/EBITDA 为 78.4×），因此亏损来自利息、折旧这类成本，而非核心业务本身。尽管账面上是亏损，它已经能产生正的自由现金流。分析师目前预计它将在 2026 年前后转为盈利。
价格区间 — 接近其历史阻力区
目前价格为 $339.66，接近其近期区间的上沿。过去一年 CRL 的价格在 $146.20 到 $351.21 之间波动；其历史支撑区在 $292.66 附近，阻力区在 $351.21 附近。它同时位于 50 日和 200 日均线上方，这在历史上通常对应上升趋势。
资金流向 — 方向不明确
CRL 近期的买卖成交量大致均衡，没有明显的吸筹或派发形态。过去 30 个交易日，上涨日的成交量约为下跌日的 1.0×。
股息与公司概况
CRL 不派发股息，但在 2025 财年回购了 3.6亿美元 的股票，约占市值的 2.5%。其股数过去一年减少了 1.7%，五年减少了 5.5%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.